Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential gene expression in C. auris in presence of pyrvinium pamoate

ABSTRACT: Differential gene expression in C. auris in presence of pyrvinium pamoate

PROVIDER: PRJNA735943 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14758158.fastq.gz	Fastqsanger.gz
	SRR14758159.fastq.gz	Fastqsanger.gz
	SRR14758160.fastq.gz	Fastqsanger.gz
	SRR14758161.fastq.gz	Fastqsanger.gz
	SRR14758162.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Differential gene expression in C. auris in presence of pyrvinium pamoate

Project description:PAT-seq approach was utilised to determine the gene expression in the the transcriptome of C. auris treated with the vehicle DMSO or drug pyrvvinium pamoate (PP). Biological triplicates of C. auris cultures grown in RPMI medium with either DMSO or 1uM PP for 30 minutes at 37 Celsius were havested and total RNA was isolated using standard procedures (hot phenol method).

2022-04-04 | GSE176354 | GEO

MIA-PaCa2 cells treated with Pyrvinium Pamoate, Rotenone, Oligomycin or Control

Project description:Purpose: To compared Pyrvinium Pamoate induced transcription changes with known mitochondrial inhibitors. Methods: MIA-PaCa2 cells were treated with Pyrvinium Pamoate at 0.3µM, Oligomycin at 4µM or rotenone at 0.5 µM for 48 hours and then RNA was collected.

2022-06-03 | GSE176305 | GEO

Identifying Targets of Pyrvinium Pamoate in Jurkat Cells using PISA

Project description:Pyrvinium pamoate, an anthelmintic drug, inhibits mitochondrial biogenesis during initial T-cell activation; however, its molecular target(s) and mechanism of action are unknown. In this study, we treated Jurkat T cell lysate with pyrvinium pamoate (5 nM and 50μM) and used proteome integral solubility alteration (PISA), to identify potential targets.

2023-08-29 | PXD040663 | Pride

Pyrvinium pamoate targets to multiple vulnerabilities of Merkel cell carcinoma

Project description:Among several WNT signaling perturbagens, we identified pyrvinium pamoate, an FDA-approved anthelminthic drug that exhibits anti-tumor abilities in multiple cancers. Through the integration of transcriptomic, network, and molecular analyses, we discovered that pyrvinium is broadly effective against Merkel cell carcinoma cell lines, and it targets multiple proposed MCC tumorigenesis pathways. Our study revealed that pyrvinium exerts anti-tumor activity in MCC not only through perturbing the canonical and non-canonical WNT signaling pathway but also non-specifically inhibiting cell growth - via the activation of the p53-mediated apoptosis pathway, modulation of mitochondrial function, and induction of endoplasmic reticulum (ER) stress.

2023-11-06 | GSE229701 | GEO

Effect of pyrvinium pamoate on transcriptome and signaling pathways in FLT3-ITD acute leukemic cell line Molm13

Project description:To identify molecular effects of a classical anthelmintic pyrvinium pamoate(PP), we applied gene expression profiling in human acute leukemic cell line FLT3-ITD+ Molm13 using Whole Transcriptome Shotgun Sequencing (RNA-seq) after 6 h treatment with 50nM or 100nM pyrvinium. We got 94 and 219 differentially expressed genes (DEGs) compared with the control group, respectively. Among 94 DEGs in the 50nM pyrvinium group, 62 were upregulated and 32 were downregulated and corresponded 162 upregulated and 57 downregulated DEGs in the 100nM pyrvinium group.

2021-12-29 | GSE153854 | GEO

Effect of acute pyrvinium pamoate treatment on gene expression of CD4+ T cells during early activation.

Project description:Treatment of T cells with pyrvinium pamoate (PP) early during their activation blocks mitochondrial biogenesis and results in reduced proliferation, skewed CD4+ T cell differentiation and reduced cytokine production. Therefore, to examine the role of PP treatment on mitochondria health, we performed gene expression analysis to identify differentially expressed genes in naive CD4+ T cells cultured with anti-CD3/CD28 plus PP or DMSO. Naive CD4+ T cells were activated for six hours with 2 mg/mL anti-CD3/anti-CD28 mAbs and activated for an additional one hour in the presence or absence of PP.

2023-08-16 | GSE229494 | GEO

Pyrvinium pamoate targets to multiple vulnerabilities of Merkel cell carcinoma

Project description:Pyrvinium pamoate targets to multiple vulnerabilities of Merkel cell carcinoma

| PRJNA955382 | ENA

MIA-PaCa2 cells treated with Pyrvinium Pamoate, Rotenone, Oligomycin or Control

Project description:MIA-PaCa2 cells treated with Pyrvinium Pamoate, Rotenone, Oligomycin or Control

| PRJNA735746 | ENA

Effect of acute pyrvinium pamoate treatment on gene expression of CD4+ T cells during early activation.

Project description:Effect of acute pyrvinium pamoate treatment on gene expression of CD4+ T cells during early activation.

| PRJNA954753 | ENA

Effect of pyrvinium pamoate on transcriptome and signaling pathways in FLT3-ITD acute leukemic cell line Molm13

Project description:Effect of pyrvinium pamoate on transcriptome and signaling pathways in FLT3-ITD acute leukemic cell line Molm13